WaveMan · Form 4
McKhann Chas insider trades
> Search tickers & screens ⌘K
LIVE

McKhann Chas insider trades

McKhann Chas has filed 10 Form 4s with the SEC that we hold, for APEN (President and CEO, Director), SILK (Chief Executive Officer, Director), Envoy Medical, Inc. (COCH) (Director) and Exagen INC. (XGN) (Director). Across all of them we count 0 purchases worth $0 and 6 sales worth $1.0M reported on Form 4. None of these purchases or sales is dated in the last 12 months. The largest single trade was a sale of 21,156 shares of APEN worth $173.7K, dated 2021-08-18. The first filing on our record is dated 2021-08-20 and the latest 2026-06-22.

APEN

President and CEO, Director · 5 filings · 6 purchases and sales
Trade dateCodeSharesValue as filedFiled
2021-08-18S, sale reported on Form 421,156$173.7K2021-08-20
2021-08-18S, sale reported on Form 421,156$173.7K2021-08-20
2021-08-19S, sale reported on Form 421,148$166.9K2021-08-20
2021-08-19S, sale reported on Form 421,148$166.9K2021-08-20
2021-08-20S, sale reported on Form 421,148$163.7K2021-08-20
2021-08-20S, sale reported on Form 421,148$163.7K2021-08-20

SILK

Chief Executive Officer, Director · 3 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Envoy Medical, Inc. (COCH)

Director · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Exagen INC. (XGN)

Director · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Source

Counted from the Form 4 filings this reporting owner (SEC CIK 1631746) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.

Source: U.S. Securities and Exchange Commission (EDGAR) and other official government data · Updated 2026-10-12 · For informational purposes only, not investment advice.
Privacy · Terms